APP
AKBA icon

Avantax Planning Partners’s Akebia Therapeutics AKBA Stock Holding History

Avantax Planning Partners’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-266
Closed -$3K – 277
2018
Q1 		$3K Buy
+266
New +$3.72K ﹤0.01% 1489

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Avantax Planning Partners's AKBA Position: Q2 2018 in Review

Avantax Planning Partners sold out of Akebia Therapeutics (AKBA) in Q2 2018, closing a stake of 266 shares — an estimated $3K sold.

Avantax Planning Partners first reported a position in AKBA in Q1 2018 and held it in 1 quarter. The position peaked at $3K in Q1 2018. 145 funds tracked by Wall St. Rank hold AKBA as of Q2 2018.

  • Avantax Planning Partners reported no remaining Akebia Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Avantax Planning Partners sold 266 Akebia Therapeutics shares in Q2 2018, an estimated $3K.
  • Avantax Planning Partners first reported a position in Akebia Therapeutics in Q1 2018 and held it in 1 quarter.
  • Avantax Planning Partners's Akebia Therapeutics position peaked at $3K in Q1 2018.
  • 145 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2018.

Based on Avantax Planning Partners's 13F filing for Q2 2018, filed 13 Aug 2018.